Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis

BACKGROUND: Fingolimod is the first approved oral disease-modifying agent (DMA) in 2010 to treat Multiple Sclerosis (MS). There is limited real-world evidence regarding the determinants associated with fingolimod use in the early years. OBJECTIVE: The objective of this study was to examine the facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Earla, Jagadeswara Rao, Hutton, George J., Thornton, J. Douglas, Chen, Hua, Johnson, Michael L., Aparasu, Rajender R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031432/
https://www.ncbi.nlm.nih.gov/pubmed/35481133
http://dx.doi.org/10.1016/j.rcsop.2021.100021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031432/
https://www.ncbi.nlm.nih.gov/pubmed/35481133
http://dx.doi.org/10.1016/j.rcsop.2021.100021

Ejemplares similares